AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Managing Vendor/CRO/CMO Oversight: 2 Day Course - London, United Kingdom - April 8th-9th, 2019 - ResearchAndMarkets.com

March 6, 2019

DUBLIN--(BUSINESS WIRE)--Mar 6, 2019--The “Managing Vendor/CRO/CMO Oversight” conference has been added to ResearchAndMarkets.com’s offering.

Learn how to prepare a Request for Proposal (RFP), evaluate and select the right CRO and establish procedures for vendor oversight for R&D projects you need to outsource.

With regulatory inspectors increasingly finding issues with vendor oversight by sponsor organisations, it is becoming increasingly important for the pharmaceutical industry to employ efficient and accurate strategies for managing outsourced activities. A company’s ability to identify and select the right CRO/ vendor for the right project and manage them efficiently and effectively will help to ensure compliance with the Regulator’s expectations.

On this course you will learn how to prepare a Request for Proposal (RFP), evaluate and select the right CRO and establish procedures for vendor oversight for R&D projects you need to outsource. You will also cover the techniques for successfully managing CROs/ vendors and the shared responsibilities required by the sponsor and the service provider. Managing CRO performance issues will also be discussed.

The course is equally useful to CROs/other vendors and consultants to understand how to work effectively with sponsor organisations.

Benefits of attending:

  • Understand how to effectively manage CROs/vendors used in the pharma industry
  • Build an understanding of your responsibilities as the sponsor and identify the right level of management and oversight
  • Discuss how to put in place a robust CRO/vendor selection process
  • Discover tools and processes to manage CROs and other vendors
  • Measure CRO performance including metrics and key performance indicators

Who Should Attend:

This course is designed for personnel involved in CRO/vendor oversight in the pharmaceutical, biotechnology, animal health and medical device industries including those working in clinical research, regulatory affairs, pharmacovigilance, manufacturing, clinical outsourcing, contracts, quality, clinical operations, vendor management and global QA/compliance. It will also be relevant for outsourcing, purchasing, finance and contract management staff who participate in the Request for Proposal (RFP) process who will find this course a valuable introduction or refresher course focusing on best practice.

This course will also help CRO/vendor personnel to work more successfully with pharmaceutical, biotechnology and medical device companies through gaining a much clearer understanding of their needs when outsourcing.

Agenda:

Introduction and Objectives

Background to the CRO Industry and Meeting Regulatory Expectations

  • Outsourcing today for the Pharma industry
  • Different models of outsourcing in the Pharma industry
  • The potential benefits and drivers of outsourcing
  • Examine EU and FDA expectations re. outsourcing for the Pharma industry

Effective Oversight: How CROs and Sponsors can Work Successfully on R & D Projects

  • Challenges of working with CROs to ensure effective management and oversight

Vendor/CRO Selection - an Overview of Selection and Bidding Processes including Assessing the Competency of the CRO / Vendor

  • All or none - what should you outsource?
  • Sponsor responsibilities for the clinical study vs the CRO
  • Writing the RFP
  • Evaluating responses to the RFP
  • Pre-qualification of vendors and vendor audits
  • Contracts, negotiations and partnering with CROs

Managing Vendor/CRO Project Set Up

  • Building effective relationship with the CRO while providing sponsor oversight and a working escalation of issues
  • How to set the stage so the CRO focuses on Quality - the quality/oversight plan
  • Briefing the CRO to be able to work successfully in the Pharma industry
  • Clarity of roles and responsibilities

Oversight Preparation, Planning, and Clarity of Roles and Responsibilities

  • Project set-up, planning and initiation with CROs for R & D projects
  • Training CROs
  • Which SOPs should CROs use?
  • Clarity and communications with CROs
  • Risk assessment tools
  • Tools and techniques for managing CRO performance - understand the KPIs / /dashboards / report processes that can be set up in order to manage regular meetings with CROs / Vendors

On-Going Oversight and Management

  • Tracking and measuring CRO progress and performance
  • On-going training and integrating new CRO staff
  • Auditing CROs
  • Maintaining effective communication with your CRO
  • Progress and update meetings / TCs with CROs
  • Agendas for meetings with CROs to include update reports
  • Discussion of billing issues with CROs
  • Deliverables and analysing performance trends
  • Troubleshooting problems with CROs - Common problems and possible solutions

End of Project Oversight: Reviewing CROs during and at the end of the Project

  • Review meetings
  • Feedback and learning’s for using the CRO in the future

Review and Final Discussion

For more information about this conference visit https://www.researchandmarkets.com/research/8mx3pf/managing?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190306005433/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Advertising and Marketing

KEYWORD: UNITED KINGDOM EUROPE

INDUSTRY KEYWORD: COMMUNICATIONS MARKETING

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/06/2019 08:45 AM/DISC: 03/06/2019 08:45 AM

http://www.businesswire.com/news/home/20190306005433/en